Page 174 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 174
Chapter 5
Supplementary Table 4. DPD enzyme activity in patients with and without severe toxicity
DPYD genotype Wild-type
c.1236G>A c.2846A>T DPYD*2A c.1679T>G
Patients without severe toxicitya
Patients with severe toxicitya P-valueb
Mean activity (SD)
9.6 (3.6) 7.6 (3.0) 6.8 (1.9) 4.9 (0.7) NA
N of patients
Mean activity (SD)
N of patients
15 0.36 13 0.79 6 0.33 3 0.22 0 NA
67 8.7 (3.7) 22 7.3 (2.6) 6 5.7 (1.8) 5 5.5 (1.1) 1 NA
a Severe toxicity is defined as CTC-AE grade 3 or higher;
b P-value determined with t-test.
Abbreviations: CTC-AE: common terminology criteria for adverse events; NA: not applicable.
172
